The fact that AmSurg shares (Ticker: AMSG) are trading at all-time highs hasn't escaped the attention of Executive Vice President David Manning. A trading plan set up last fall by the veteran development exec on Monday exercised about 12,000 stock options that would have expired in 2017 and then sold the resulting shares. His profit on the transactions tops $345,000.
Equity investors last week lapped up the news that AmSurg plans to acquire physician services company Sheridan for more than $2 billion, but debt ratings agency Moody's isn't nearly as ebullient. Analysts Ron NeySmith and Peter Abdill say they are putting AmSurg's Ba3 rating under review for a downgrade because the Sheridan deal will push the company's debt levels to about six times its EBITDA. CFO Claire Gulmi last week said the AmSurg team expects to quickly work that ratio back down into the 4s, but the Moody's analysts say they see the Sheridan transaction marking a shift to "a much more aggressive acquisition strategy."
Color John Ransom enthusiastic about AmSurg's game-changing play for Sheridan Healthcare. The veteran Raymond James analyst has upgraded shares of the ambulatory surgery company all the way to 'strong buy' from 'market perform' and sees the stock (Ticker: AMSG) rising to $60 from the $45.74 where it closed Thursday. Ransom also has raised his 2015 EPS estimate for AmSurg to $3.15 from $2.77.
Shares of LifePoint Hospitals hit an all-time high of $63.07 Friday morning thanks in part to an upgrade from Ann Hynes at Mizuho. Hynes now rates the hospital operator a 'buy' instead of a 'neutral' and has raised her target to $72 from $58. LifePoint shares (Ticker: LPNT) are up almost 2 percent to $61.99 in late-morning trading.
POSTDATA: WARRANTY DEEDS